Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00272779 · ClinicalTrials.gov registry record · Phase 3
BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,057
- Enrollment target
NCT00272779 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,057 participants.
The verdict
NCT00272779, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,057 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and antiviral effects of atazanavir (ATV) plus ritonavir (RTV) versus a combination drug of lopinavir (LPV) plus RTV. A combination drug containing tenofovir (TDF) and emtricitabine (FTC) will also be taken by participants in both arms.
Interventions
- DRUG ATV
- DRUG RTV
- DRUG Tenofovi-Emtricitabine (TDF/FTC) tablet
- DRUG LPV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,057 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00272779
The ClinicalTrials.gov registry entry for NCT00272779 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,057 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ATV is the first listed.
NCT00272779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00272779 about?
NCT00272779 is a clinical study titled "BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada". The purpose of this study is to evaluate the safety, tolerability and antiviral effects of atazanavir (ATV) plus ritonavir (RTV) versus a combination drug of lopinavir (LPV) plus RTV. A combination drug containing tenofovir (TDF) and emtricitabine (FTC) will also be taken by participants in both arm...
What is the current status of trial NCT00272779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,057 participants. The study started on 2005-11. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00272779?
The interventions under investigation include: ATV (DRUG), RTV (DRUG), Tenofovi-Emtricitabine (TDF/FTC) tablet (DRUG), LPV (DRUG).
Who is sponsoring clinical trial NCT00272779?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.